Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

BMC cancer - 16 Oct 2015

Melchardt Thomas, Hufnagl Clemens, Magnes Teresa, Weiss Lukas, Hutarew Georg, Neureiter Daniel, Schlattau Alexander, Moser Gerhard, Gaggl Alexander, Tränkenschuh Wolfgang, Greil Richard, Egle Alexander

Abstract excerpt

BACKGROUND: Induction chemotherapy incorporating docetaxel, cisplatin and 5- fluorouracil before radiotherapy may improve the outcome of patients with advanced head and neck cancer. Nevertheless, the addition of docetaxel increases hematological toxicity and infectious complications. Therefore, genetic markers predicting toxicity and efficacy of this treatment regimen may help to identify patients, who would have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Docetaxel

Share to Fluorouracil

Share to Head and Neck Neoplasms

Share to Induction Chemotherapy

Share to Steroid Hydroxylases

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 26475344
DOI: 10.1186/s12885-015-1776-x
PMCID: PMC4609094

Genes

ERCC1
ERCC2
XRCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.PMID 26475344Read ↗

An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel.Semantic proximity Read ↗

Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.Semantic proximity Read ↗

The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.Semantic proximity Read ↗

ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.Semantic proximity Read ↗

Association between genetic polymorphisms in SLC19A1, SLCO1B1 and SLCO1B3 genes predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapySemantic proximity Read ↗

Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.Semantic proximity Read ↗

Polymorphisms in solute carrier genes (SLC19A1, SLCO1B1, and SLCO1B3) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.Semantic proximity Read ↗

Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.Semantic proximity Read ↗

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.Semantic proximity Read ↗

Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohortSemantic proximity Read ↗

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.Semantic proximity Read ↗

Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.